Gujarat Themis Biosyn (NSE:GUJTHEM) Cyclically Adjusted Revenue per Share: ₹10.98 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GUJTHEM Gujarat Themis Biosyn Ltd NSE:GUJTHEM
67 GF Score
Price ₹367.55
GF Value ₹313.52
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Gujarat Themis Biosyn Cyclically Adjusted Revenue per Share?

Gujarat Themis Biosyn NSE:GUJTHEM +3.26% 67 Cyclically Adjusted Revenue per Share is ₹10.98 as of Mar. 2026. GuruFocus rates NSE:GUJTHEM with a GF Score™ of 67/100 and a GF Value™ of ₹313.52 (Modestly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Gujarat Themis Biosyn's adjusted revenue per share for the three months ended in Mar. 2026 was ₹4.061. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹10.98 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Gujarat Themis Biosyn's average Cyclically Adjusted Revenue Growth Rate was 15.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 16.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 18.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Gujarat Themis Biosyn was 20.10% per year. The lowest was 16.30% per year. And the median was 18.30% per year.

As of today (2026-08-11), Gujarat Themis Biosyn's current stock price is ₹367.55. Gujarat Themis Biosyn's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₹10.98. Gujarat Themis Biosyn's Cyclically Adjusted PS Ratio of today is 33.47.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Gujarat Themis Biosyn was 44.87. The lowest was 5.68. And the median was 15.70.


Gujarat Themis Biosyn  (NSE:GUJTHEM) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Gujarat Themis Biosyn's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=367.55/10.98
=33.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Gujarat Themis Biosyn was 44.87. The lowest was 5.68. And the median was 15.70.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Gujarat Themis Biosyn Cyclically Adjusted Revenue per Share Related Terms


Gujarat Themis Biosyn Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Gujarat Themis Biosyn's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gujarat Themis Biosyn Cyclically Adjusted Revenue per Share Chart

Gujarat Themis Biosyn Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 9.56 10.98

Gujarat Themis Biosyn Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.56 9.90 10.26 10.64 10.98

NSE:GUJTHEM vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Gujarat Themis Biosyn's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gujarat Themis Biosyn Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gujarat Themis Biosyn's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Gujarat Themis Biosyn's Cyclically Adjusted PS Ratio falls into.


NSE:GUJTHEM
67GF Score
Gujarat Themis Biosyn Ltd NSE:GUJTHEM
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gujarat Themis Biosyn Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Gujarat Themis Biosyn's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.061/164.2724*164.2724
=4.061

Current CPI (Mar. 2026) = 164.2724.

Gujarat Themis Biosyn Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.771 105.961 1.195
201609 0.008 105.961 0.012
201612 0.780 105.196 1.218
201703 0.955 105.196 1.491
201706 0.871 107.109 1.336
201709 0.873 109.021 1.315
201712 0.900 109.404 1.351
201803 0.919 109.786 1.375
201806 0.949 111.317 1.400
201809 0.964 115.142 1.375
201812 0.905 115.142 1.291
201903 0.936 118.202 1.301
201906 1.072 120.880 1.457
201909 1.507 123.175 2.010
201912 2.808 126.235 3.654
202003 2.402 124.705 3.164
202006 1.439 127.000 1.861
202009 2.496 130.118 3.151
202012 2.239 130.889 2.810
202103 2.124 131.771 2.648
202106 2.976 134.084 3.646
202109 3.215 135.847 3.888
202112 1.707 138.161 2.030
202203 2.578 138.822 3.051
202206 4.124 142.347 4.759
202209 4.377 144.661 4.970
202212 2.585 145.763 2.913
202303 2.509 146.865 2.806
202306 4.552 150.280 4.976
202309 3.625 151.492 3.931
202312 3.546 152.924 3.809
202403 3.859 153.035 4.142
202406 3.549 155.789 3.742
202409 3.187 157.882 3.316
202412 3.625 158.323 3.761
202503 3.460 157.552 3.608
202506 3.286 159.755 3.379
202509 3.889 162.289 3.937
202512 3.966 163.281 3.990
202603 4.061 164.272 4.061

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹10.98 mean?
Gujarat Themis Biosyn (NSE:GUJTHEM) has a Cyclically Adjusted Revenue per Share of ₹10.98 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Gujarat Themis Biosyn and its competitors.
Is Gujarat Themis Biosyn's Cyclically Adjusted Revenue per Share too high?
Gujarat Themis Biosyn's current Cyclically Adjusted Revenue per Share is ₹10.98. Overall, Gujarat Themis Biosyn has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gujarat Themis Biosyn's Cyclically Adjusted Revenue per Share compare to ZTS?
Gujarat Themis Biosyn's Cyclically Adjusted Revenue per Share of ₹10.98 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Gujarat Themis Biosyn and its competitors. Gujarat Themis Biosyn's current Cyclically Adjusted Revenue per Share is ₹10.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gujarat Themis Biosyn stock overvalued right now?
Based on GuruFocus' analysis, Gujarat Themis Biosyn (NSE:GUJTHEM) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹313.52, compared to a current price of ₹367.55 — trading 17.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹10.98. Gujarat Themis Biosyn's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Gujarat Themis Biosyn (NSE:GUJTHEM), the current Cyclically Adjusted Revenue per Share is ₹10.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gujarat Themis Biosyn (NSE:GUJTHEM) Overvalued in 2026?

Based on GuruFocus' analysis, Gujarat Themis Biosyn stock appears to be overvalued. The current stock price of ₹367.55 is trading 17.2% above its estimated GF Value™ of ₹313.52. GuruFocus considers Gujarat Themis Biosyn to be Modestly Overvalued.

Key valuation signals for NSE:GUJTHEM:

  • Cyclically Adjusted Revenue per Share: ₹10.98
  • GF Value™: ₹313.52 vs. price of ₹367.55 (17.2% above fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the NSE:GUJTHEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gujarat Themis Biosyn Business Description

Other Exchanges 506879:India
Address S.V Road, Themis House, 11/12 Udyog Nagar, Goregaon (West), Mumbai, MH, IND, 400104
Gujarat Themis Biosyn Ltd is engaged in manufacturing, exporting, and selling of bulk drugs on a job-work basis. The company operates in one segment which is pharmaceuticals. Its products include Rifamycin-S, which is an intermediate for Rifampicin for the treatment of tuberculosis (TB), and Lovastatin.
67GF Score

Get the complete analysis for NSE:GUJTHEM

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹367.55
Price
₹313.52
GF Value